Zura Bio Analyst Price Targets - Benzinga

Zura Bio Ltd

ZURANASDAQ

Trade with Public

Trade with Public

$3.81

-0.045-1.17%

마지막 업데이트: Oct 30, 11:04 AM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

Zura Bio Analyst Price Targets - Benzinga

Zura Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Zura Bio (ZURA).

Price Target Range — 9 Quarters

Analyst Consensus — 10 Analysts

9Buy

1Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$14Upside to Avg. PT+279.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 12, 2026	Wedbush	Martin Fan	PT Raise	Outperform	$15→$22
Aug 12, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$15→$20
Jul 8, 2026	William Blair	Matt Phipps	Initiate	Outperform	—
Jul 1, 2026	Wedbush	Martin Fan	Maintained	Outperform	$15
Mar 23, 2026	Chardan Capital	Daniil Gataulin	PT Raise	Buy	$10→$11
Mar 20, 2026	Oppenheimer	Justin Kim	PT Cut	Outperform	$16→$15
Feb 9, 2026	Wedbush	Martin Fan	Initiate	Outperform	$15
Nov 14, 2025	Chardan Capital	Daniil Gataulin	Maintained	Buy	$10
Nov 13, 2025	Clear Street	Kaveri Pohlman	Initiate	Buy	$18
Sep 30, 2025	Chardan Capital	Daniil Gataulin	Maintained	Buy	$10
Aug 19, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Neutral	$3→$2
Aug 15, 2025	Oppenheimer	Justin Kim	PT Cut	Outperform	$17→$16
Aug 15, 2025	Chardan Capital	Daniil Gataulin	Maintained	Buy	$10
May 9, 2025	Oppenheimer	Jeff Jones	PT Cut	Outperform	$19→$17
Apr 3, 2025	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Neutral	$5→$3
Mar 26, 2025	Oppenheimer	Jeff Jones	PT Cut	Outperform	$20→$19
Mar 26, 2025	Guggenheim	Yatin Suneja	Maintained	Buy	$15
Mar 26, 2025	Chardan Capital	Matthew Barcus	PT Cut	Buy	$12→$10
Dec 24, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Neutral	$5
Dec 11, 2024	Cantor Fitzgerald	Josh Schimmer	Maintained	Overweight	—

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22

Wedbush analyst Martin Fan maintains Zura Bio (NASDAQ:ZURA) with a Outperform and raises the price target from $15 to $22.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20

Guggenheim analyst Yatin Suneja maintains Zura Bio (NASDAQ:ZURA) with a Buy and raises the price target from $15 to $20.

Benzinga Newsdesk

PRO
William Blair Initiates Coverage On Zura Bio with Outperform Rating

William Blair analyst Matt Phipps initiates coverage on Zura Bio (NASDAQ:ZURA) with a Outperform rating.

Benzinga Newsdesk

Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy

William Blair starts Zura Bio (NASDAQ: ZURA) at Outperform, citing tibulizumab's multibillion-dollar potential in autoimmune disease.

Vandana Singh

PRO
Wedbush Reiterates Outperform on Zura Bio, Maintains $15 Price Target

Wedbush analyst Martin Fan reiterates Zura Bio (NASDAQ:ZURA) with a Outperform and maintains $15 price target.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Zura Bio, Lowers Price Target to $15

Oppenheimer analyst Justin Kim maintains Zura Bio (NASDAQ:ZURA) with a Outperform and lowers the price target from $16 to $15.

Benzinga Newsdesk